Thrombosis and Cancer Immunotherapy: The Next Frontier of Thromboinflammation

Thrombosis and Cancer Immunotherapy The Next Frontier of Thromboinflammation Review Abstract Cancer immunotherapy has fundamentally transformed the treatment landscape across multiple malignancies, offering durable responses and prolonged survival in patients with previously limited therapeutic options. Immune checkpoint inhibitors, chimeric antigen receptor T cell therapies, bispecific antibodies,

Controversies in Antiphospholipid Syndrome: DOACs vs. Warfarin

Controversies in Antiphospholipid Syndrome: DOACs vs. Warfarin  Check out our extensive video library (see channel for our latest videos) Abstract Antiphospholipid syndrome (APS) represents a complex autoimmune disorder characterized by thrombotic events and pregnancy complications in patients with persistent antiphospholipid antibodies. The traditional anticoagulant

Anticoagulation Therapy In Risky Geriatric Cardiac Patients

Anticoagulation Therapy In Risky Geriatric Cardiac Patients In the realm of cardiovascular health, the coexistence of atrial fibrillation (AF) with heart failure (HF) presents a significant challenge for anticoagulation, particularly in the aging population. Uncertainties abound regarding treatment efficacy and patient outcomes. The All Nippon AF In the Elderly (ANAFIE) Registry,

Radiation therapy And VTE Risk

Radiation therapy And VTE Risk Thromboembolic events are often the primary cause of complications in malignancies. They also have a major effect on the morbidity and mortality of cancer patients. Compared to chemotherapy and other kinds of systemic therapies, there’s not enough data about the impact of ionizing radiation on the

Thrombosis and Cancer Immunotherapy: The Next Frontier of Thromboinflammation